Figure 2.
Changes in the absolute lymphocyte count (ALC) with ipilimumab therapy are shown. (A) The ALC of all patients at baseline and after 1 and 2 doses of ipilimumab is shown. (B) The change in ALC for each patient with therapy is shown.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.